GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » Cyclically Adjusted Price-to-FCF

Orchestra BioMed Holdings (Orchestra BioMed Holdings) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Orchestra BioMed Holdings Cyclically Adjusted Price-to-FCF?

Orchestra BioMed Holdings does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Orchestra BioMed Holdings Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Orchestra BioMed Holdings's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchestra BioMed Holdings Cyclically Adjusted Price-to-FCF Chart

Orchestra BioMed Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
- - - -

Orchestra BioMed Holdings Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Orchestra BioMed Holdings's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Orchestra BioMed Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orchestra BioMed Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Orchestra BioMed Holdings's Cyclically Adjusted Price-to-FCF falls into.



Orchestra BioMed Holdings Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Orchestra BioMed Holdings does not have a history long enough to calculate Cyclically Adjusted FCF per Share. Therefore GuruFocus does not calculate Cyclically Adjusted Price-to-FCF for this company.


Orchestra BioMed Holdings  (NAS:OBIO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Orchestra BioMed Holdings Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Orchestra BioMed Holdings's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description

Traded in Other Exchanges
N/A
Address
150 Union Square Drive,, New Hope, PA, USA, 18938
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
Executives
George Papandreou officer: See Remarks C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Eric S Fain director ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
David P Hochman director, officer: See Remarks 15 WESTON HILL RD., RIVERSIDE CT 06878
Joshua Aiello officer: Principal Accounting Officer 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Yuval Mika officer: See Remarks 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Pamela Ann Connealy director 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Darren Sherman director, officer: See Remarks C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Rose Eric A Md director 161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Andrew Lawrence Taylor officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
William Reed Little officer: See Remarks C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Plc Medtronic 10 percent owner 20 ON HATCH, LOWER HATCH STREET, DUBLIN L2 2
Michael Kaswan officer: Chief Financial Officer KBL HEALTHCARE ACQUISITION CORP II, 645 MADISON AVENUE, NEW YORK NY 10022
Geoffrey Wade Smith director 6740 SHADY OAK ROAD, EDEN PRAIRIE MN 55344
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014